FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung

Full Text:


Aim: to conduct a pharmacoeconomic analysis of chemotherapy taking into account the types of malignant neoplasms of the bronchi and lung, and to calculate pharmacoeconomic efficiency.

Materials and methods. The materials for the study were the data of the Moscow Cancer Hospital n.a. D.D. Pletnev for 2019. The cost of drugs was calculated according to the data of the website (for June 2019).

Results and discussion. For 300 patients with squamous non-small cell lung cancer, it is required 3205.5 courses of chemotherapy of I (1747.5) and II (1458) lines. For 200 patients with non-small cell non-squamous EGFR positive lung cancer, it is required 1,413.1 courses of chemotherapy and targeted therapy. For 70 patients with non-squamous cell non-small cell lung cancer with ALK mutation, it is required 450.2 courses of chemotherapy and targeted therapy. For 280 patients with non-squamous cell non-small cell lung cancer lung cancer without mutations, it is required 7515 chemotherapy courses. For 150 patients with small cell lung cancer, it is required 1,656.8 courses of chemotherapy. Thus, a total sample of 1000 patients, excluding the type of malignant neoplasm of broncus and lung are required 14,239.8 chemotherapy courses. The determined cost of 67,000 rubles for the average chemotherapy course per patient takes into account the necessary colony stimulating factors, antiemetic, infusion solutions, etc.; in the case of treatment with erlotinib (the length of the course is 8 months), the cost is 663,408.0 rubles; in the case of treatment with crizotinib (the length of the course is 11 months course), the cost is 2044110.0 rubles. The average cost of drug therapy for one patient with malignant neoplasm of bronchus and lung is 1136155.9 rubles.

Conclusion. We determined the pharmacoeconomic dependence of a chemotherapy on the type of malignant neoplasms of bronchus and lung and the main anticancer drug used. The median of the overall survival rate of patients with malignant neoplasms of bronchus and lung was 42 months. The average cost of drug therapy was 27051.3 rubles per month. The median survival rate without therapy is 3 months. Thus, therapy can extend the patient’s life by an average of 39 months. The cost of a month of a saved life is 29132.2 rubles. 

About the Authors

S. K. Yarovoy
N.A. Lopatkin Research Institute of Urology and Interventional Radiology ; D.D. Pletnev City Clinical Hospital of the Moscow City Health Department
Russian Federation

Sergey K. Yarovoy – MD, Dr Sci Med, Chief Researcher, Lopatkin‘s scientific research institute of urology and interventional radiology – branch ;  clinical pharmacologist

51 3rd Parkovaya St., Moscow 105425; 32 11th Parkovaya St., Moscow 105077

I. B. Shikina
Central Research Institute of Health Organization and Informatization; Central State Medical Academy of the Presidential Administration of the Russian Federation
Russian Federation

Irina B. Shikina – MD, Dr Sci Med, Assistant Professor, Chief Researcher, office of the organization of planning and management of scientific researches;  professor the organization of health care and public health, medical insurance and state control in health sector 

Dobrolyubova St., 11, Moscow 127254; 19-1A Marshal Timoshenko St., Moscow 121359


1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics. 1998. Cancer J. Сlin. 1998; 48:6-29.

2. Ivanova A.E., Didenko I.S., Semenova V.G., Zemlyanova E.V., Sharova E.A. Phenomenon of cancer-related mortality in Russia in the 1990s. Obshchestvennoe zdorov’e i profilaktika zabolevaniy (in Russ). 2005;12(4):16-21.

3. Kelly K. Future Directions for new cytotoxic agents in the treatment of advanced stage non-small-cell lung cancer. ASCO 2000. Educational Book. 357-367.

4. Malignant new growths in Russia in 2017 (incidence and mortality). Under the editorship of A.D. Kaprin, V.V. Starinsky, G.V. Petrova. M. (in Russ). 2018; 250 p.

5. Antipova T.V., Melnik M.V., Nechayeva O.B., Shikina I.B., Vechorko V.I., Lutseva E.M. Assessment of the effectiveness of medical care for cancer. Social aspects of health of the population. 2016; 1 (47). DOI: 10.21045/2071-5021-2016-47-1-3. (in Russ). [Electronic resource] URL:,ru/. Accessed: 12.01.2020.

6. Johnson B.E. Integration of New Agents into the treatment of advanced non-small-cell lung cancer. ASCO 2000. Educational Book. 354-356.

7. Gorbunova V.A. Lung cancer chemotherapy. Russian medical Journal. (in Russ). 2001;5:186.

8. Giaccone G. Neoadjuvant Chemotherapy in locally advanced NSCLC. 4th Pan-European Cancer-Symposium – A New Era in the Management of Lung Cancer. Cannes. France. 2000. Abstract book. 19–20.

9. Kolbin A.S., Kurylev A.A., Pavlysh A.V. Pharmacoeconomic expediency of use of medicine of locally-spread or metastatic non-small cell cancer of lung with a mutation of a epidermal growth factor receptor (EGFR). Modern oncology. 2014;2 (16): 66–73 (in Russ).

10. Qian H., Gao F, Wang H., Ma F. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014; 14: 683. [Electronic resource] URL: https://www.ncbi. Accessed: 12.01.2020.

11. Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;278(2):113–125.

12. Soria J.C., Wu Y.L., Nakagawa K. et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive nonsmall-cell lung cancer after progression on firstline gefi tinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–98.

13. Saito H., Fukuhara T. et al. Erlotinib plus beva-cizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35.

14. Nakamura A., Inoue A. et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced nonsmall cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Journal of Clinical Oncology. 2018 May 20;36(15):9005–9005.

15. Belousov Yu.B., Konstantinova M.M., Pavlysh A.V. Gefitinib in treatment of non-small cell cancer of lung: clinic and economic justification. Modern oncology. 2010;2:32-39 (in Russ).

16. Semiglazova T.Yu., Zhabina A.S., Belyaeva A.B., Klyuge V.A., Usova K.V., Latipova D.H., Teletayeva G.M., Novik A.V., Semyonova A.I., Protsenko S.A. Target therapy of NMRL with the activa ting mutations of EGFR improves quality of life. Medical council. 2016;10:56-65 (in Russ). DOI: 10.21518/2079-701X-2016-10-56-65.

17. Orlov S.V., Lozhkina A.M., Odintsovo S.V., Sviridenko M.A., Cheremnykh A.O., Urgenova M.A., Filippova E.A. Erlotinib in the combined therapy of a widespread adenocarcinoma of a lung in the presence of egfr gene mutation. Medical council. 2019;10:64-71 (in Russ). DOI: 10.21518/2079-701X-2019-10-64-71.

18. Laktionov K.K., Yudin D.I., Breder V.V., Reutov E.V., Laktionov K.P., Marinova D.T., Peregudov D.A., Ardzinba M.S. Preliminary results of the integrated chemotherapy with EGFR receptor tyrosinekinase inhibitors at patients with non-small cell cancer of a lung and activating EGFR gene mutation. Medical council. 2019;10:110-114 (in Russ). DOI: 10.21518/2079-701X-2019-10110-114.

19. Ksalkori: new opportunities of target therapy of ALK positive non-small cell cancer of lung. Effective pharmacotherapy. Oncology, hematology and radiology. 2015;4 (52): 40–47 (in Russ).

20. Kulikov A.Yu., Zinchuk I.Yu., Pavlov P.V. The pharmacoecono mic analysis of use of medicine crizotinib in the first line of chemothe rapy of ALK positive non-small cell cancer of lung. Pharmakoekonomika: theory and practice. 2014;1 (2):21-24 (in Russ). DOI: 10.30809/phe.1.2014.46.

For citation:

Yarovoy S.K., Shikina I.B. The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(1):13-22. (In Russ.)

Views: 180

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)